Door-to-balloon delays with PCI in acute myocardial infarction

Current Treatment Options in Cardiovascular Medicine

Volumn 6, Issue 1, 2004, Pages 69-77

  Guerra, Daniel R ^b   Gibson, C Michael ^a  

^a PERFUSE Angiographic Core Laboratory   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY CARE UNIT; DISEASE DURATION; ELECTROCARDIOGRAM; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEALTH PROGRAM; HEART CATHETERIZATION; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; MORTALITY; PATIENT CARE; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; REGISTER; REVIEW; SYMPTOMATOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 3142671376     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-004-0016-5     Document Type: Review

References (50)

1. Braunwald E: The open artery is alive and well again. N Engl J Med 1993, 329:1650-1652.
2. Indications for fibrinolytic therapy in suspected acute myocardial infarction: calloborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trailists' (FIT) Collaborative Group [no authors listed]. Lancet 1994, 343:311-322.
3. Goldberg RJ, Mooradd M, Gurwitz JH, et al.: Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction). Am J Cardiol 1998, 82:259-264.
4. Newby LK, Rutsch WR, Califf RM, et al.: Time from symptom onset to treatment and outcomes after thrombolytic therapy. The GUSTO-1 Invetigators]. N Engl J Med 1993, 329:673-682.
5. An international randomized trail comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Angiographic Investigators [no authors listed]. N Engl J Med 1993, 329:673-682.
6. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators [no authors listed]. N Engl J Med 1993, 329:1615-1622.
7. A clinical trial comparing primary coronary angioplasty with tissue palsminogen activator for acute myocardial infarction. GUSTO IIb investigators [no authors listed]. N Engl Med 1997, 336:1621-1628.
8. Grines CL, Cox DA, Stone GW. et al.: Coronary angioplasty or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999, 341:1949-1956.
9. Bode C, Smalling RW, et al.: Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and fron-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation 1996, 94:891-898.
10. Cannon CP, Gibson CM, McCabe CH, et al.: TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B Investigators. Circulation 1998, 98:2805-2814.
11. Weaver WD, Simes RJ, Betriu A, et al.: Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997, 278:2093-2098.
12. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13-20.
13. Cannon CP, Antman EM, Walls R, Braunwald E: Time as an adjuntive agent to thrombolytic therapy. J Thromb Thrombolysis 1994, 1:27-34.
14. Rogers WJ, Dean LS, Moore PB, et al.: Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Alabama Registry of Myocardial Ischemia Investigators. Am J Cardiol 1994, 74:11-118.
15. Every NR, Parsons LS, Hlatky M, et al.: A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. Myocardial Infarction Triage and Intervention Investigators. N Engl J Med 1996, 335:1253-1260.
16. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial infarction Study Group. N Engl J Med 1993, 328:673-679.
17. Zijlstra F, de Boer MJ, Hoorntje JC, et al.: A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993, 328:680-684.
18. Braunwald E: Optimizing thrombolytic therapy of acute myocardial infarction. Circulation 1990, 82:1510-1513.
19. Cannon CP: Time to treatment: a crucial factor in thrombolysis and primary angioplasty. J Thromb Thrombolysis 1996, 3:249-255.
20. Brodie BR, Stuckey TD, Wall TC, et al.: Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998, 32:1312-1319.
21. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infaction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators [no authors listed]. N Engl J Med 1997, 336:1621-1628.
22. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators [no authors listed]. N Engl J Med 1996, 335:775-782.
23. Berger PB, Ellis SG, Holmes DR Jr, et al.: Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO-IIb) trial. Circulation 1999, 100:14-20.
24. Cannon CP, Gibson CM, Lambrew CT, et al.: Relationship of symptom-onset-to ballon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000, 283:2941-2947.
25. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127:757-763.
26. Joffe MM, Rosenbaum PR: Invited commentary: propensity scores. Am J Epidemiol 1999, 150:327-333.
27. Ryan TJ, Anderson JL, Antman EM, et al.: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996, 28:1328-1428.
28. Ryan TJ, Antman EM, Brooks NH, et al.: 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999, 34:890-911.
29. Brodie BR, Stone GW, Morice MC, et al.: Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). Am J Cardiol 2001, 88:1085-1090.
30. Antoniucci D, Valenti R, Migliorini A, et al.: Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 2002, 89:1248-1252.
31. Brodie BR, Stuckey TD, Muncy DB, et al.: Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention. Am Heart J 2003, 145:708-715.
32. Caputo RP, Ho KK, Stoler RC, et al.: Effect of continous quality improvement analysis on the delivery of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1997, 79:1159-1164.
33. Ward MR, Lo ST, Herity NA, et al.: Effect of audit on door-to-inflation times in primary angioplasty/stenting for acute myocardial infarction. Am J Cardiol 2001, 87:336-338, A339.
34. Shry EA, Eckart RE, Winslow JB, et al.: Effect of monitoring of physician performance on door-to-balloon time for primary angioplasty in acute myocardial infarction. Am J Cardiol 2003, 91:867-869.
35. Canto JG, Rogers WJ, Bowlby LJ, et al.: The prehospital electrodiagram in acute myocardial infarction: is its full potential being realized? National Registry of Myocardial Infarction 2 Investigators. J Am Coll Cardiol 1997, 29:498-505.
36. Lenfant C, LaRosa JH, Horan MJ, Passamani ER: Considerations for a national heart attack alert program. Clin Cardiol 1990, 13:VIII9-VIII11.
37. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. National Heart Attack Alert Program Coordinating Committee, 60 Minutes to Treatment Working Group [no authors listed]. Ann Emerg Med 1994, 23:311-329.
38. 9-1-1: rapid identification and treatment of acute myocardial infarction. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee [no authors listed]. Am J Emerg Med 1995, 13:188-195.
39. Emergency medical dispatching: rapid identification and treatment of acute myocardial infarction. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee [no authors listed]. Am J Emerg Med 1995, 13:67-73.
40. Staffing and equipping emergency medical services systems: rapid identification and treatment of acute myocardial infarction. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee [no authors listed]. Am J Emerg Med 1995, 13:58-66.
41. Krall SP, Reese CLT, Donahue L: Effect of continuous quality improvement methods on reducing triage to thrombolytic interval for acute myocardial infarction Acad Emerg Med 1995, 2:603-609.
42. Hand M, Brown C, Horan M, Simons-Morton D: The National Heart Attack Alert Program: progressive at 5 years in educating providers, patients, and the public and future directions. J Thromb Thrombolysis 1998, 6:9-17.
43. Cannon CP, Johnson EB, Cermignani M, et al.: Emergency department thrombolysis critical pathway reduces door-to-drug times in acute myocardial infarction. Clin Cardiol 1999, 22:17-20.
44. Zalenski RJ, Selker HP, Cannon CP, et al.: National Heart Attack Alert Program position paper: chest pain centers and programs for the evaluation of acute cardiac ischemia. Ann Emerg Med 2000, 35:462-471.
45. Karagounis L, Ipsen SK, Jessop MR, et al.: Impact of field-transmitted electrodiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1990, 66:786-791.
46. Weaver WD, Eisenberg MS, Martin JS, et al.: Myocardial Infarction Triage and Intervention Project - phase I: patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. J Am Coll Cardiol 1990, 15:925-931.
47. Kereiakes DJ, Gibler WB, Martin LH, et al.: Relative importance of emergency medical system transport and the prehospital electrodiagram on reducing hospital time delay to therapy for acute myocardial infarction: a preliminary report from the Cincinnati Heart Project. Am Heart J 1992, 123:835-840.
48. Magid DJ, Calonge BN, Rumsfeld JS, et al.: Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA 2000, 284:3131-3138.
49. Canto JG, Every NR, Magid DJ, et al.: The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. N Engl J Med 2000, 342:1573-1580.
50. Angeja BG, Gibson CM, Chin R, et al.: Predictors of door-to-balloon delay in primary angioplasty. Am J Cardiol 2002, 89:1156-1161.